• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.研究性肽脱甲酰酶抑制剂NVP LBM-415与其他药物对人支原体和脲原体的体外活性比较
Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. doi: 10.1128/AAC.49.6.2541-2542.2005.
2
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.新型氟喹诺酮类药物DC-159a与其他抗菌药物对人支原体和脲原体的体外活性比较
Antimicrob Agents Chemother. 2008 Oct;52(10):3776-8. doi: 10.1128/AAC.00849-08. Epub 2008 Jul 28.
3
Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.新型氟喹诺酮类药物ABT-492与其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性比较
Antimicrob Agents Chemother. 2003 Dec;47(12):3973-5. doi: 10.1128/AAC.47.12.3973-3975.2003.
4
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.人型支原体和脲原体对新型研究性酮内酯类药物CEM-101的体外敏感性比较
Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.
5
Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.苯并喹喔啉氟喹诺酮类左氧氟沙星（WCK 771）和其他抗菌药物对人类支原体和脲原体的活性，包括具有明确耐药机制的分离株。
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01348-18. Print 2018 Nov.
6
Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.格帕沙星（GSK2140944）及其他抗菌药物对人型支原体和脲原体的活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01064-17. Print 2017 Oct.
7
In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.强力霉素、四环素、红霉素及一种新型大环内酯类抗生素CP 62993对肺炎支原体、人型支原体和解脲脲原体活性的体外比较
Scand J Infect Dis Suppl. 1988;53:12-7.
8
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.加替沙星（BMS - 284756）及其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
9
In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.奥马环素（PTK 0796）及其他抗菌药物对人型支原体和脲原体的体外活性
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7502-7504. doi: 10.1128/AAC.01734-16. Print 2016 Dec.
10
In vitro activities of ABT-773 and other antimicrobials against human mycoplasmas.ABT-773及其他抗菌药物对人型支原体的体外活性
Antimicrob Agents Chemother. 2003 Jan;47(1):39-42. doi: 10.1128/AAC.47.1.39-42.2003.

引用本文的文献

1
Metal utilization in genome-reduced bacteria: Do human mycoplasmas rely on iron?基因组简化细菌中的金属利用：人型支原体是否依赖铁？
Comput Struct Biotechnol J. 2021 Oct 18;19:5752-5761. doi: 10.1016/j.csbj.2021.10.022. eCollection 2021.
2
Drug forecast - the peptide deformylase inhibitors as antibacterial agents.药物预测——肽酰基转移酶抑制剂作为抗菌剂。
Ther Clin Risk Manag. 2007 Aug;3(4):513-25.
3
Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.阿奇霉素缓释剂：美国治疗急性细菌性鼻窦炎和社区获得性肺炎的应用综述
Drugs. 2007;67(5):773-92. doi: 10.2165/00003495-200767050-00010.
4
Activity of LBM415 compared to those of 11 other agents against Haemophilus species.与其他11种药物相比，LBM415对嗜血杆菌属的活性。
Antimicrob Agents Chemother. 2006 Jul;50(7):2323-9. doi: 10.1128/AAC.00106-06.

本文引用的文献

1
The genome sequence of Mycoplasma hyopneumoniae strain 232, the agent of swine mycoplasmosis.猪支原体病病原体——猪肺炎支原体232菌株的基因组序列。
J Bacteriol. 2004 Nov;186(21):7123-33. doi: 10.1128/JB.186.21.7123-7133.2004.
2
Mycoplasma pneumoniae and its role as a human pathogen.肺炎支原体及其作为人类病原体的作用。
Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004.
3
Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents.新型肽脱甲酰基酶抑制剂LBM415与其他药物相比的抗葡萄球菌活性。
Antimicrob Agents Chemother. 2004 Oct;48(10):4033-6. doi: 10.1128/AAC.48.10.4033-4036.2004.
4
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.一种肽脱甲酰基酶抑制剂（NVP PDF - 713）对耐恶唑烷酮或耐链阳菌素革兰氏阳性菌分离株的潜在效用。
J Antimicrob Chemother. 2004 May;53(5):804-7. doi: 10.1093/jac/dkh184. Epub 2004 Mar 31.
5
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitor.NVP-PDF 713（一种新型肽脱甲酰基酶抑制剂）的纸片扩散法质量控制指南。
Diagn Microbiol Infect Dis. 2004 Jan;48(1):55-7. doi: 10.1016/S0732-8893(03)00162-7.
6
Resistance to anti-peptide deformylase drugs.
Expert Opin Ther Targets. 2001 Jun;5(3):415-418. doi: 10.1517/14728222.5.3.415.
7
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.加替沙星（BMS - 284756）及其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
8
Peptide deformylase as an antibacterial drug target: target validation and resistance development.肽脱甲酰基酶作为抗菌药物靶点：靶点验证与耐药性产生
Antimicrob Agents Chemother. 2001 Apr;45(4):1058-64. doi: 10.1128/AAC.45.4.1058-1064.2001.
9
The complete sequence of the mucosal pathogen Ureaplasma urealyticum.解脲脲原体这种黏膜病原体的完整序列。
Nature. 2000 Oct 12;407(6805):757-62. doi: 10.1038/35037619.
10
Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents.肽脱甲酰基酶作为新一代广谱抗菌剂的作用靶点。
Mol Microbiol. 2000 Jun;36(6):1197-205. doi: 10.1046/j.1365-2958.2000.01908.x.

研究性肽脱甲酰酶抑制剂NVP LBM-415与其他药物对人支原体和脲原体的体外活性比较

Comparative in vitro activities of investigational peptide deformylase inhibitor NVP LBM-415 and other agents against human mycoplasmas and ureaplasmas.

作者信息

Waites Ken B, Reddy Nipun B, Crabb Donna M, Duffy Lynn B

机构信息

Department of Pathology, WP 230, 619 19th Street South, Birmingham, AL 35249, USA.

出版信息

Antimicrob Agents Chemother. 2005 Jun;49(6):2541-2. doi: 10.1128/AAC.49.6.2541-2542.2005.

DOI:10.1128/AAC.49.6.2541-2542.2005
PMID:15917568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1140545/
Abstract

Peptide deformylase inhibitor LBM-415 and seven other drugs were tested against Mycoplasma pneumoniae (100 isolates), Mycoplasma hominis (20 isolates), Mycoplasma fermentans (10 isolates), and Ureaplasma species (50 isolates). LBM-415 was active against M. pneumoniae (MICs, <or=0.008 microg/ml). It showed no activity against M. hominis and M. fermentans and modest activity against Ureaplasma spp.

摘要

肽脱甲酰基酶抑制剂LBM - 415以及其他七种药物针对肺炎支原体（100株分离株）、人型支原体（20株分离株）、发酵支原体（10株分离株）和解脲脲原体属（50株分离株）进行了测试。LBM - 415对肺炎支原体有活性（最低抑菌浓度，≤0.008微克/毫升）。它对人型支原体和发酵支原体无活性，对解脲脲原体属有适度活性。